Molecular Mechanisms Behind Neurodegenerative Diseases: Alzheimer's and Parkinson's

Introduction

Neurodegenerative diseases, such as Alzheimer's disease (AD) and Parkinson's disease (PD), are major health challenges, particularly in aging populations. These conditions involve the gradual loss of neurons, leading to severe cognitive and motor impairments. While significant research has been conducted on these diseases, the precise molecular mechanisms remain complex and not fully understood. This paper explores the molecular mechanisms behind Alzheimer's and Parkinson's disease and considers potential strategies to prevent or delay their onset. 

Molecular Mechanisms in Alzheimer's Disease

Alzheimer's disease, the most common cause of dementia, is mainly characterized by progressive memory loss and cognitive decline. The disease’s molecular causes are largely related to the accumulation of amyloid-beta plaques and tau tangles within the brain.

   Amyloid-beta is a peptide formed from the amyloid precursor protein (APP). Normally, APP is processed by enzymes, such as beta-secretase and gamma-secretase, which result in smaller fragments. In Alzheimer's disease, these amyloid-beta fragments form plaques that build up outside neurons. These plaques are toxic to brain cells, disrupting communication between neurons, causing inflammation, and increasing oxidative stress, all of which contribute to neuronal death and the cognitive decline observed in Alzheimer's . 

Another key feature of Alzheimer's disease is the buildup of tau protein. Tau helps stabilize the structure of neurons by supporting microtubules, which are responsible for transporting essential materials within cells. However, in Alzheimer's, tau becomes abnormally modified and forms twisted tangles inside neurons. These tangles interfere with normal cellular functions, particularly the movement of nutrients and signals within the neuron, leading to its dysfunction and eventual death.

Genetic factors are also an important part of the development of Alzheimer's disease. The Apolipoprotein E (APOE) gene is a major genetic risk factor, especially the APOE ε4 allele, which is strongly associated with an increased risk of Alzheimer's. Additionally, mutations in the presenilin 1 and presenilin 2 genes can lead to early-onset forms of Alzheimer's.

Molecular Mechanisms in Parkinson's Disease

Parkinson's disease is a neurodegenerative disorder that mainly affects motor control, leading to tremors, rigidity, and bradykinesia (slowness of movement). Parkinson's disease is caused by the loss of dopamine-producing neurons in the substantia nigra, a region of the brain involved in movement regulation. The molecular processes involved in Parkinson’s include the abnormal accumulation of alpha-synuclein, mitochondrial dysfunction, and neuroinflammation.

Alpha-synuclein is a protein that plays a role in neurotransmitter release at synaptic junctions. 

  In Parkinson’s disease, this protein misfolds and aggregates, forming clumps known as Lewy bodies inside neurons. These Lewy bodies contribute to neuronal dysfunction, particularly in dopaminergic neurons of the substantia nigra, and lead to motor symptoms. The accumulation of alpha-synuclein is thought to trigger a series of destructive events, including oxidative stress and inflammation, which worsen neuronal damage. Mitochondrial dysfunction is also a central factor in Parkinson’s disease. Mitochondria are responsible for providing energy to cells, and their dysfunction leads to reduced energy production and the accumulation of harmful reactive oxygen species (ROS), which damage neurons. This process accelerates the death of dopaminergic neurons, further impairing motor control.

Neuroinflammation plays an additional role in Parkinson's disease. Microglial cells, which are the brain’s immune cells, become activated in response to neuronal injury. These activated cells release inflammatory signals that increase the damage to surrounding neurons. Chronic inflammation may also encourage the buildup of alpha-synuclein, creating a cycle of neuronal damage Several genetic factors contribute to Parkinson’s disease, including mutations in the SNCA gene, which encodes alpha-synuclein. Other mutations in the LRRK2 and PARK7 genes have also been identified in familial forms of the disease, though these mutations are not the sole cause of Parkinson’s.

Prevention and Delay of Onset

While there is currently no cure for Alzheimer's or Parkinson’s disease, various approaches aim to prevent or delay the onset of these diseases. In Alzheimer's disease, treatments focus on managing symptoms and slowing progression. Cholinesterase inhibitors, such as donepezil, are commonly used to treat cognitive decline, but they do not stop the disease's progression. Recently, therapies targeting amyloid-beta plaques, such as aducanumab, have been developed. These treatments aim to reduce the accumulation of amyloid plaques, although their effectiveness remains debated. In Parkinson’s disease, levodopa remains the main treatment, as it increases dopamine levels to improve motor function. However, it does not prevent the degeneration of neurons or stop the disease from advancing. Research into new treatments, such as gene therapy, aims to address the underlying causes of the disease, such as preventing the misfolding of alpha-synuclein or improving mitochondrial function.

In addition to medical treatments, lifestyle factors play an important role in reducing the risk of neurodegenerative diseases. Regular physical activity has been shown to improve brain health, reduce inflammation, and enhance neuroplasticity, which may help preserve cognitive and motor function.  A diet rich in antioxidants, such as the Mediterranean diet, may protect against the oxidative stress that contributes to both Alzheimer's and Parkinson's disease. Emerging technologies, such as gene editing with CRISPR/Cas9, may offer future avenues for treating these diseases at a genetic level. These technologies could allow for the correction of harmful genetic mutations or the alteration of pathways involved in disease development, potentially preventing or slowing the progression of Alzheimer's and Parkinson's disease.

Conclusion

Alzheimer's and Parkinson's diseases are complex conditions with distinct molecular mechanisms. Alzheimer's is characterized by amyloid-beta plaques and tau tangles, while Parkinson's disease involves alpha-synuclein aggregation, mitochondrial dysfunction, and neuroinflammation. Although our understanding of these diseases has improved, there is still no cure. Current treatments focus on symptom management, but advancements in gene therapy, and pharmacological interventions hold promise for slowing disease progression or even preventing these conditions. Ongoing research into the molecular underpinnings of Alzheimer's and Parkinson's disease will be important in developing more effective therapies.

Works Cited

İş, Özkan, et al. "Gliovascular Transcriptional Perturbations in Alzheimer’s Disease Reveal Molecular Mechanisms of Blood Brain Barrier Dysfunction." Nature Communications 15.1 (2024): 4758. ProQuest. 21 Dec. 2024 .

Sepúlveda-Lara, Alexis, Paulina Sepúlveda, and Gabriel Nasri Marzuca-Nassr. "Resistance Exercise Training as a New Trend in Alzheimer’s Disease Research: From Molecular Mechanisms to Prevention." International Journal of Molecular Sciences 25.13 (2024): 7084. ProQuest. 21 Dec. 2024 .

Qiu, Kaixin, et al. "TMP21 in Alzheimer’s Disease: Molecular Mechanisms and a Potential Target." Frontiers in Cellular Neuroscience (2019) ProQuest. 21 Dec. 2024 .

de Vries, Luuk,E., et al. "The Concept of Resilience to Alzheimer’s Disease: Current Definitions and Cellular and Molecular Mechanisms." Molecular Neurodegeneration 19 (2024): 1-33. ProQuest. 21 Dec. 2024 .

Clausen, Lene, et al. "PRKN-Linked Familial Parkinson’s Disease: Cellular and Molecular Mechanisms of Disease-Linked Variants." Cellular and Molecular Life Sciences 81.1 (2024): 223. ProQuest. 21 Dec. 2024

Dong-Chen, Xu, et al. "Signaling Pathways in Parkinson’s Disease: Molecular Mechanisms and Therapeutic Interventions." Signal Transduction and Targeted Therapy 8.1 (2023): 73. ProQuest. 21 Dec. 2024 .

Jiang, Jiehui, et al. "Editorial: Translational Advances in Alzheimer's, Parkinson's, and Other Dementia: Molecular Mechanisms, Biomarkers, Diagnosis, and Therapies, Volume III." Frontiers in Aging Neuroscience (2024) ProQuest. 21

Yingying, Gu, et al. "Olfactory Dysfunction and its Related Molecular Mechanisms in Parkinson’s Disease." Neural Regeneration Research 19.3 (2024): 583-90. ProQuest. 21 Dec. 2024 .

Coskuner-Weber, Orkid, and Vladimir N. Uversky. "Insights into the Molecular Mechanisms of Alzheimer’s and Parkinson’s Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology." International Journal of Molecular Sciences 19.2 (2018): 336. ProQuest. 21 Dec. 2024 .

Ratan, Yashumati, et al. "Advancements in Genetic and Biochemical Insights: Unraveling the Etiopathogenesis of Neurodegeneration in Parkinson’s Disease." Biomolecules 14.1 (2024): 73. ProQuest. 21 Dec. 2024 .